BiotechTube

LBH589 + Epoetin Alfa

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndrome (MDS)

Conditions

Myelodysplastic Syndrome (MDS)

Trial Timeline

Nov 1, 2009 → Aug 1, 2012

NCT ID
NCT01034657

About LBH589 + Epoetin Alfa

LBH589 + Epoetin Alfa is a phase 2 stage product being developed by Novartis for Myelodysplastic Syndrome (MDS). The current trial status is terminated. This product is registered under clinical trial identifier NCT01034657. Target conditions include Myelodysplastic Syndrome (MDS).

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndrome (MDS) were approved

Approved (7) Terminated (7) Active (7)
✅decitabine + azacitidineEisaiApproved
✅DeferasiroxNovartisApproved
✅ICL670/DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01034657Phase 2Terminated

Competing Products

20 competing products in Myelodysplastic Syndrome (MDS)

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Erlotinib HydrochlorideAstellas PharmaPhase 2
35
Decitabine + Decitabine + DecitabineEisaiPhase 2
35
Decitabine + Valproic AcidEisaiPhase 2
35
decitabine + decitabineEisaiPhase 2
35
decitabine + azacitidineEisaiApproved
35
DecitabineEisaiPhase 2
27
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
29
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
35
Subcutaneous DecitabineEisaiPhase 1
21
DecitabineEisaiPhase 2
35
Galunisertib + PlaceboEli LillyPhase 2/3
38
DSP-7888Sumitomo PharmaPhase 1/2
32
TP-0184Sumitomo PharmaPhase 1/2
24
DecitabineJohnson & JohnsonPhase 2
35
Epoetin alfaJohnson & JohnsonPhase 2
27
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
35